Specifically, nintedanib acts on the pathways that are regulated by vascular endothelial growth factor (VEGF), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs), and these data revealed significant suppression of tumor development by nintedanib in human NSCLC xenograft models, as well as other tumors [20]. Here, VEGFA is linked to non-small cell lung carcinoma.